Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00321620|
Recruitment Status : Completed
First Posted : May 4, 2006
Results First Posted : March 21, 2014
Last Update Posted : March 21, 2016
|Condition or disease||Intervention/treatment||Phase|
|Bone Metastases||Drug: zoledronic acid Biological: denosumab||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1904 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer|
|Study Start Date :||April 2006|
|Primary Completion Date :||October 2009|
|Study Completion Date :||February 2012|
|Active Comparator: zoledronic acid||
Drug: zoledronic acid
Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Other Name: Zometa
Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
- Time to the First On-Study SRE (Non-inferiority) [ Time Frame: Up to 40.5 months ]Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.
- Time to the First On-Study SRE (Superiority) [ Time Frame: Up to 40.5 months ]Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.
- Time to the First-And-Subsequent On-Study SRE [ Time Frame: Up to 40.5 months ]
Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.
This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00321620